Search Results

81 - 90 of 90 items :

  • pharmacokinetics x
  • Internal Medicine x
Clear All
Zastosowanie infuzyjnego schematu chemioterapii DA-EPOCH w leczeniu chłoniaków agresywnych

] schedule, and pharmacokinetics would improve outcome in patients with large B-cell lymphomas. A prospective multi-institutional study of administration of etoposide, vincristine, and doxorubicin for 96 hours with bolus doses of cyclophosphamide and oral prednisone (EPOCH therapy. Schemat chemioterapii EPOCH z podaniem leków w dawkach dostosowywanych, z lub bez dodatku rituximabu (DA-EPOCH(-R), dose adjusted -EPOCH - rituximab) jest leczeniem wykorzystującym długotrwałą infuzję cytostatyków, z modyfikacją dawek w kolejnych cyklach na podstawie obserwowanych parametrow

Open access
Review. Perioperative Management of Lactic Acidosis in End-Stage Liver Disease Patient

. Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis. Clin Pharmacol Ther 1999;66:380-390. 55. Nahas GG1, Sutin KM, Fermon C, et al. Guidelines for the treatment of acidaemia with THAM. Drugs. 1998;55:191-224. 56. Hoste EA, Colpaert K, Vanholder RC, et al. Sodium bicarbonate versus THAM in ICU patients with mild metabolic acidosis. J Nephrol. 2005;18:303-307. 57. Kraut J A, Madias NE. Treatment of acute metabolic acidosis: a pathophysiologic approach Nat. Rev. Nephrol 2012

Open access
Progressive arthropathy in the course of immune tolerance induction failure in a child with hemophilia A and FVIII inhibitor – a case report

with hemophilia A with inhibitors: results from the HAVEN 2 study Blood 2018 132 suppl 1 632 (abstr) [13] Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019. Published online April 16, 2019. Pipe SW Shima M Lehle M et al Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre

Open access
Implantoprosthetic rehabilitation of a patient with severe form of hemophilia B: a case report

subcommittee of factor VIII and factor IX of the scientific and standarization committee of the International Society on Thrombosis and Haemostasis Thromb Haemost. 2001 85 560 [4] Lehmann-Kopydlowska M, Zawilska K. Dental guidelines in congenital hemophilia A and B. Czas Stomatol. 2010;63(6):345-357. Lehmann-Kopydlowska M Zawilska K. Dental guidelines in congenital hemophilia A and B Czas Stomatol. 2010 63 6 345 357 [5] Bjorkman S, Carlsson M, Berntop E. Pharmacokinetics of factor IX in patients with haemophilia B: Methodological aspects and physiological interpretation

Open access
Medication-Related Osteonecrosis of the Jaw: a Brief Review, Treatment and Practical Guidelines for Dentists

of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res . 2007;86:1022. 34. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone . 2011;48:677. 35. Suzuki K, Takeyama S, Sakai Y, Yamada S, Shinoda H. Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts. J Pharmacol Sci . 2006;100:189. 36. Ito M, Amizuka N

Open access
Increased Susceptibility to Postoperative PCA Morphine-Induced Respiratory Depression in a Patient with an Undiagnosed Traumatic Porencephalic Cyst – A Case Report

neurosurgical consultation. The patient and the family disclosed that the patient had not had any prior cranial imaging since the initial traumatic event. Discussion It is not entirely clear if the increased susceptibility to postoperative low-dose PCA morphine-induced respiratory depression in the patient with a large undiagnosed post-traumatic porencephalic cyst was due to functional changes in the pharmacokinetics and pharmacodynamics related to the structural changes of the brain. A porencephalic cyst is a cavity in the cerebral hemisphere filled with

Open access
Stosowanie leków biopodobnych w hematoonkologii – stanowisko Polskiego Towarzystwa Hematologów i Transfuzjologów

Kanakasetty GB et al Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study Lancet Haematol 2017 4 e350 61 [8] Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017;4:e362

Open access
Radiology of the adrenal incidentalomas. Review of the literature

. Unal E, Karaosmanoglu A, Akata D, Ozmen MN, Karcaaltincaba M. Invisible fat on CT: making it visible by MRI. Diagn Interv Radiol 22, 133-140, 2016. van Niel MB, Collins I, Beer MS, Broughton HB, Cheng SK, Goodacre SC, Heald A, Locker KL, MacLeod AM, Morrison D, Moyes CR, O’Connor D, Pike A, Rowley M, Russell MG, Sohal B, Stanton JA, Th omas S, Verrier H, Watt AP, Castro JL. Fluorination of 3-(3-(piperidin-1-yl) propyl) indoles and 3-(3-(piperazin-1-yl) propyl) indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profi

Open access
A short review of primary aldosteronism in a question and answer fashion

, Lim RC, Siperstein AE, Clark OH, Schecter WP, Hunt TK, Horn JK, Duh QY. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Arch Surg 134, 628-632, 1999. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10, 23-29, 2005. So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI, Stowasser M. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J

Open access
Novel insights into genetics and clinics of the HNF1A-MODY

subtypes. Diabetologia 54, 2801–2810, 2011. Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmoller J. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron. Pharmacogenomics J 12, 22–29, 2012. Tzvetkov MV, Saadatmand AR, Lotsch J, Tegeder I, Stingl JC, Brockmoller J. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug Tramadol. Clin Pharmacol Ther 90, 143–150, 2011

Open access